Alkermes (ALKS) Net Cash Flow Growth (5y) (2015 - 2026)
Alkermes (ALKS) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.44% |
| Dec 31, 2025 | 73.41% |
| Sep 30, 2025 | 12.93% |
| Jun 30, 2025 | 56.49% |
| Mar 31, 2025 | 42.72% |
| Dec 31, 2024 | -12.77% |
| Sep 30, 2024 | -32.74% |
| Jun 30, 2024 | 42.65% |
| Mar 31, 2024 | 2.43% |
| Dec 31, 2023 | -41.89% |
| Sep 30, 2023 | -18.13% |
| Jun 30, 2023 | 67.63% |
| Mar 31, 2023 | 51.72% |
| Dec 31, 2022 | 1.73% |
| Sep 30, 2022 | 5.82% |
| Jun 30, 2022 | -3.77% |
| Mar 31, 2022 | -61.08% |
| Dec 31, 2021 | 29.97% |
| Sep 30, 2021 | 55.12% |
| Jun 30, 2021 | 76.38% |